key: cord-0860306-13gamveq
authors: Gilham, Dean; Smith, Audrey L; Fu, Li; Moore, Dalia Y; Muralidharan, Abenaya; Reid, St. Patrick M; Stotz, Stephanie C; Johansson, Jan O; Sweeney, Michael; Wong, Norman CW; Kulikowski, Ewelina; El-Gamal, Dalia
title: Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
date: 2021-03-11
journal: bioRxiv
DOI: 10.1101/2021.03.10.432949
sha: 2f65b66f32935f66aeb0ad80e676dfc1cd271428
doc_id: 860306
cord_uid: 13gamveq

Effective therapeutics are urgently needed to counter infection and improve outcomes for patients suffering from COVID-19 and to combat this pandemic. Manipulation of epigenetic machinery to influence viral infectivity of host cells is a relatively unexplored area. The bromodomain and extraterminal (BET) family of epigenetic readers have been reported to modulate SARS-CoV-2 infection. Herein, we demonstrate apabetalone, the most clinical advanced BET inhibitor, downregulates expression of cell surface receptors involved in SARS-CoV-2 entry, including angiotensin-converting enzyme 2 (ACE2) and dipeptidyl-peptidase 4 (DPP4 or CD26) in SARS-CoV-2 permissive cells. Moreover, we show that apabetalone inhibits SARS-CoV-2 infection in vitro to levels comparable to antiviral agents. Taken together, our study supports further evaluation of apabetalone to treat COVID-19, either alone or in combination with emerging therapeutics. Graphical Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease of 2019 (COVID-19) 1 , a pandemic that has caused more than 2 million deaths worldwide, and continues to be a public health emergency 2 . Infected patients present with a wide range of clinical manifestations, including cough, fatigue, and temperature dysregulation (fever / chills) 3 . Unfortunately, 10-20% of infected patients progress to severe disease requiring hospitalization, and ~5% of patients become critically ill 4 . Moreover, ~10-50% patients have long-term health consequences following acute SARS-CoV-2infection that impact cognitive, cardiovascular, and renal function [5] [6] [7] . A dysregulated hyperinflammatory immune response, or cytokine storm, causes harmful widespread tissue damage and is strongly associated with rapidly deteriorating outcomes -viral pneumonia, acute respiratory distress syndrome (ARDS), severe lung injury, multi-organ failure and ultimately death 1, 8 . The high rate of COVID-19 complications and mortality underscore the urgent need for effective therapies, not only to reduce the severity of SARS-CoV-2 infection and improve outcomes, but to support ongoing vaccination efforts that may be compromised by emerging variants of the virus. SARS-CoV-2 is typically transmitted through the inhalation of aerosols and respiratory droplets 9 . Infection is initiated by binding of the viral spike protein to the transmembrane receptor angiotensin-converting enzyme 2 (ACE2) on host cells, followed by fusion of the viral coat with the cell membrane 10, 11 . ACE2 washed with phosphate buffered saline (PBS), permeabilized in 0.1% Triton X solution for 15 min, then blocked in 3% bovine serum albumin-PBS solution. The cells were incubated with anti-Spike protein Rab (Sino Biological) at 1:1000 in blocking solution overnight at 4°C, followed by incubation with 1:2000 diluted Alexa Fluor 488 conjugated secondary antibody (Thermo Fisher) for 1 h at room temperature. Cell nuclei were counterstained using Hoechst 33342 and cytoplasmic membranes were stained with CellMask (Invitrogen). Internal control conditions were included in each plate (i.e., untreated virus infected and non-infected cells). Cells were imaged using a high content analysis system, Operetta CLS (PerkinElmer).

Percentage inhibition of viral infection and cell viability (i.e., treatment-induced cytotoxicity) were calculated using Harmony 4.9 software.

Statistical significance was determined through one-way ANOVA followed by Dunnett's multiple comparison test. Comparisons were done vs. vehicle control and p<0.05 was considered statistically significant.

Apabetalone downregulates ACE2 gene expression in multiple cell types ACE2 mediates SARS-CoV-2 attachment and entry to host cells 10, 11 , and ACE2 gene expression may be driven by BET proteins 22 . Therefore, we investigated the effect of apabetalone on ACE2 gene expression in SARS-CoV-2 permissible cell lines including human lung epithelial cells; Calu-3, and monkey kidney epithelial cells; Vero E6. In Calu-3 cells, 48 h of apabetalone treatment resulted in dose dependent reduction in hACE2 transcripts by up to 90%, p<0.001 (Fig. 1A) . In Vero E6, 24 h of 5 µM and 20 µM apabetalone treatment resulted in reduction of RhACE2 transcripts by ~40% (p<0.001) and 80% (p<0.001) respectively (Fig. 1B) . As ACE2 is expressed outside of the lung in tissues also susceptible to SARS-CoV-2 infection 33, 34 , we assessed ACE2 gene expression in extrapulmonary cells. A dose dependent decrease in hACE2 mRNA was observed in apabetalone treated liver cell culture systems including HepG2 and Huh-7 hepatocarcinoma cells (Fig. 1C -D) and PHH derived from 3 donors of different ages and genders ( Fig. 1E ; PHH donor characteristics in Supplemental Table S1 ). BETi with different chemical scaffolds and mechanism of action were included as positive controls: JQ1 is a pan-BETi with equal affinity for BET bromodomains BD1 and BD2 35 , while MZ1 is a proteolysis targeting chimera (PROTAC) that directs BET proteins for degradation 36 . Each BETi, including apabetalone, promoted downregulation of ACE2 gene expression in the cell types tested (Fig. 1) , confirming BET proteins play a pivotal role in the regulation of ACE2 gene expression in a variety of cell types.

Immunoblots examining total cell lysates showed that 48 h of BETi treatment reduced ACE2 protein in Calu-3 cells by 40-50% ( Fig. 2A and Fig. S4 ) and in Vero E6 by 25-50% ( Fig. 2B and Fig. S5 ). As membrane bound ACE2 protein is critical for SARS-CoV-2 entry 10 , BETi effects on ACE2 abundance on the cell surface were assessed using flow cytometry ( Fig. 2C-E) . In Calu-3 cells, 72 h of apabetalone treatment dose dependently reduced the amount of cell surface ACE2 levels by up to 84%, p<0.001 (Fig. 2D ). JQ1 or MZ1 treatments also reduced ACE2 protein levels, indicating reduction in ACE2 was an on-target effect of BETi, and consistent with downregulation of hACE2 gene expression (Fig. 1B) .

Vero E6 cells responded similarly to BETi treatment: apabetalone (25 µM) reduced cell surface expression of ACE2 by ~40%, p=0.047 (Fig. 2E) . Thus, BETi treatment lowered the abundance of ACE2 in both lung and kidney cells, with potential to impede SARS-CoV-2 infection or replication, as cells that do not express ACE2 have low susceptibility to SARS-CoV-2 infection 10 .

Apabetalone downregulates DPP4 (CD26) expression CD26 (gene name DPP4) is a potential cofactor for SARS-CoV-2 entry into host cells, as its presence on the cell surface facilitates viral attachment 27, 28 . In Calu-3 cells, 48 h of apabetalone treatment resulted in dose dependent downregulation in DPP4 mRNA (up to 65%, p<0.001 Fig. S1A ), in line with reduction of cell surface CD26 (up to 40% reduction, p<0.001 Fig. S1B ). Cell surface CD26 was also reduced with 48 h of BETi treatment in Karpas-299 T cells (Fig. S1C ). JQ1 and MZ1 evoked similar responses, indicating BET proteins regulate DPP4 / CD26 expression in Calu-3 lung epithelial cells and Karpas-299 T cells.

To model viral association with host cells, we measured binding of recombinant SARS-CoV-2 spike protein receptor-binding domain fused with the human IgG1 Fc-epitope (spike-RBD) to Calu-3 or Vero E6 cells.

Apabetalone pre-treatment for 72 h dose dependently attenuated the amount of spike-RBD protein bound to Calu-3 cells by more than 80% ( Fig. 3A -B, p<0.001). The comparator BETi, MZ1 and JQ1, were also efficacious.

In Vero E6 cells, 48 h of apabetalone pre-treatment reduced the amount of spike-RBD binding up to 45%, p=0.002 (Fig. 3C ). Together, these results indicate BET inhibitors reduce levels of SARS-CoV-2 spike-protein association with host cells capable of propagating the virus.

Lung epithelial Calu-3 cells are known to support infection of SARS-CoV-2 37 . Given the substantial reduction in spike-RBD binding, BETi may impede infection by SARS-CoV-2. To test this, Calu-3 cells were pre-treated with BETi for 48 h, washed, then infected with SARS-CoV-2 for 48 h (Fig. 4A) . Remarkably, viral replication was significantly impaired in cells pre-treated for 48 h with 20 µM apabetalone and remained 55-75% efficacious at concentrations below 5 µM (Fig. 4B,D) . Though ACE2 mRNA and levels of cell surface ACE2 recovered somewhat during the SARS-CoV-2 infection period (Fig. S2 ), viral replication remained markedly suppressed. Remdesivir, a ribonucleotide analogue that inhibits viral RNA polymerases 38 , also abolished SARS-CoV-2 replication as expected (Fig. 4B ). Prior to binding ACE2, the viral spike protein is primed via proteolytic cleavage by the host cell transmembrane serine protease 2 (TMPRSS2) 10 . Camostat mesylate is a serine protease inhibitor that targets TMPRSS2 39 . Pre-treatment of Calu-3 cells with 2.5 to 50 µM camostat mesylate prevented viral infection completely and reinforce how spike protein priming is a required step to initiate infection. Importantly, compound treatments were not toxic (Fig. 4C) .

Together, apabetalone was equally effective at inhibiting SARS-CoV-2 infection as agents that target viral entry or genome replication.

SARS-CoV-2 infection is initiated via SARS-CoV-2 spike protein interactions with ACE2 in cells along the respiratory tract, and uptake may be facilitated by cofactors like DPP4 / CD26 as it is for other coronaviruses 27 . Viral infection leads to cytopathic injury as viral infection spreads to ACE2 expressing cell types outside of the lung [13] [14] [15] . In severe disease, excessive, uncontrolled production of inflammatory mediators generates a cytokine storm and potential for multiorgan dysfunction 40 . In this study, we report apabetalone, the most clinically advanced BETi with BD2 selectivity, reduces SARS-CoV-2 infection in cell culture models through downregulation of viral uptake receptors. Previous studies have demonstrated apabetalone suppresses activation of innate and adaptive immune responses 31, [41] [42] [43] [44] , and thus apabetalone may reduce both SARS-CoV-2 infection and control hyperinflammatory conditions associated with poor outcomes in a dual mechanism of action.

BET proteins contain two tandem bromodomains, BD1 and BD2, that bind acetylated lysine on histone tails and transcription factors 45 . Compared to pan-BETi that target both bromodomains, selective inhibition of individual bromodomains (BD selective) results in distinct transcriptional outcomes and biological consequences 46, 47 . Apabetalone is a BETi that preferentially targets BD2, which differentiates it from pan-BETi, including JQ1 35, 48 . Toxicities have arisen in clinical trials with pan-BETi, necessitating close monitoring of patients and modified treatment schedules 24 . Apabetalone is generally well tolerated and in phase 3 clinical development for cardiovascular and renal indications 25, 26, 49, 50 .

Previous reports have indicated ACE2 gene expression is regulated by BET proteins 22 Remdesivir has been FDA approved for COVID-19 in those who are hospitalized with severe symptoms, despite the World Health Organization reporting the drug had little to no effect on 28 day mortality and did not delay the need for ventilation or shorten patients' stay in hospital 51 . Camostat mesylate, a protease inhibitor that prevents proteolytic priming of SARS-CoV-2 spike protein by TMPRSS2 to enable ACE2 binding, is still under investigation as an intervention for COVID-19 (ClinicalTrials.gov Identifiers NCT04353284, NCT04524663, NCT04470544 and others). Importantly, treatment with BETi was not toxic to Calu-3 cells at the concentrations applied in the current study (Fig. S3) .

Taken together, our results show apabetalone reduces SARS-CoV-2 infection in vitro and suggest benefit of apabetalone in COVID-19 pathology arising in ACE2 expressing cell types. Direct infection of the heart remains enigmatic; however, a recent report has described apabetalone-mediated downregulation of shown to suppress T cell proliferation and production of proinflammatory cytokines 57 . In our study, apabetalone downregulated DPP4 gene expression and CD26 cell surface protein levels in human Calu-3 lung cells and Karpas-299 T cells (Fig. S1) , in agreement with a recent report confirming BET mediated regulation of DPP4 expression 37 . The data imply therapeutic benefit through reduced viral uptake facilitated by CD26 as well as attenuation of aberrant inflammatory processes associated with severe COVID-19.

In patients with SARS-CoV-2, circulating monocytes and infiltrating macrophages increase in number, which may explain elevated levels of pro-inflammatory cytokines like interleukin (IL)-6, IL-1, tumor necrosis factor-alpha (TNF-), and IL-8 1 

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper

Epidemiology of COVID-19 Among Children in China

The Stanford Hall consensus statement for post-COVID-19 rehabilitation

Long-term Health Consequences of COVID-19

Management of post-acute covid-19 in primary care

The COVID-19 Cytokine Storm; What We Know So Far

Airborne Transmission of COVID-19: Aerosol Dispersion, Lung Deposition, and Virus-Receptor Interactions

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural basis for the recognition of SARS-CoV-2 by fulllength human ACE2

Coronavirus biology and replication: implications for SARS-CoV-2

SARS-CoV-2 and viral sepsis: observations and hypotheses

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

Extrapulmonary complications of COVID-19: A multisystem disease

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2

Suppression of inflammation by a synthetic histone mimic

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With

Apabetalone downregulates factors and pathways associated with vascular calcification

RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

NIH Image to ImageJ: 25 years of image analysis

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

The protein expression profile of ACE2 in human tissues. Molecular systems biology

Selective inhibition of BET bromodomains

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

The New England journal of medicine

A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice

BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

Epigenetic Modulation by

Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)

Histone recognition and large-scale structural analysis of the human bromodomain family

Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist

Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease

Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease

Covid-19: Remdesivir has little or no impact on survival, WHO trial shows

Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator

Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions

Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. American journal of cardiovascular drugs : drugs, devices, and other interventions

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)

Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system